ATRI:NSD-Atrion Corporation (USD)

COMMON STOCK | Medical Instruments & Supplies | NSD

Last Closing Price

USD 624.55

Change

-25.95 (-3.99)%

Market Cap

USD 1.11B

Volume

0.01M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Atrion Corporation (ATRI) Stock Analysis:
Based on the Atrion Corporation stock forecasts from 0 analysts, the average analyst target price for Atrion Corporation is not available over the next 12 months. Atrion Corporation’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Atrion Corporation is Neutral, which is based on 7 positive signals and 8 negative signals. At the last closing, Atrion Corporation’s stock price was USD 624.55. Atrion Corporation’s stock price has changed by -35.45% over the past week, -34.92% over the past month and -10.78% over the last year.

No recent analyst target price found for Atrion Corporation
No recent average analyst rating found for Atrion Corporation

About

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Germany, and internationally. Its fluid delivery products include valves that fill, hold, and re ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-25 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ISRG Intuitive Surgical Inc

-7.84 (-2.88%)

USD96.29B 57.84 56.84
HOLX Hologic Inc

-0.86 (-1.21%)

USD17.76B 9.80 7.26
MASI Masimo Corporation

-10.53 (-4.71%)

USD11.77B 53.02 49.11
XRAY DENTSPLY SIRONA Inc

-1.16 (-2.15%)

USD11.51B 27.68 14.28
RGEN Repligen Corporation

-4.39 (-2.31%)

USD10.16B 87.49 73.96
NVCR NovoCure Limited

-4.53 (-6.57%)

USD7.39B 1,480.87 4,066.85
AZTA Azenta Inc

-2.35 (-2.88%)

USD5.76B 51.78 406.97
ICUI ICU Medical Inc

-5.54 (-2.60%)

USD5.00B 41.87 18.69
STAA STAAR Surgical Company

-5.15 (-6.89%)

USD3.56B 159.38 123.68
MMSI Merit Medical Systems Inc

-2.30 (-4.00%)

USD3.14B 72.72 25.40

ETFs Containing ATRI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.40% 62% D- 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.40% 62% D- 43% F
Trailing 12 Months  
Capital Gain -10.78% 64% D 47% F
Dividend Return 1.06% 75% C 21% F
Total Return -9.72% 64% D 47% F
Trailing 5 Years  
Capital Gain 32.01% 36% F 56% F
Dividend Return 6.21% 50% F 22% F
Total Return 38.23% 39% F 54% F
Average Annual (5 Year Horizon)  
Capital Gain 5.38% 22% F 44% F
Dividend Return 0.88% 50% F 25% F
Total Return 6.26% 22% F 41% F
Risk Return Profile  
Volatility (Standard Deviation) 20.29% 100% A+ 74% C
Risk Adjusted Return 30.84% 34% F 49% F
Market Capitalization 1.11B 62% D- 69% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 34.87 59% F 26% F
Price/Book Ratio 5.26 38% F 24% F
Price / Cash Flow Ratio 28.33 25% F 14% F
EV/EBITDA 25.53 52% F 28% F
Management Effectiveness  
Return on Equity 13.53% 81% B- 75% C
Return on Invested Capital 12.26% 81% B- 81% B-
Return on Assets 8.11% 81% B- 89% B+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 11.40 5% F 4% F
Short Percent 6.35% 16% F 26% F
Beta 0.08 89% B+ 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector